NEW YORK, Nov. 2, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter recently conducted interviews with CEO Jeffrey Yordon of Sagent Pharmaceuticals and Sharif Oussa, Managing Director of Blue Energy Limited (ASX:BUL), in which they discuss growing their companies through their large portfolios. The interviews can be heard, or downloaded, at www.WallStreetReporter.com.
CEO Jeffrey Yordon of Sagent Pharmaceuticals tells us, "We currently have a pipeline that's being developed of over 200 products. As I previously stated, in the next two years, we will file over 100 submissions." Yordon adds, "That will be augmented with looking at the short-term and bringing in some approved products to supplement our short-term revenue. We believe that in 2008 there will be a very nice revenue jump."
Highlights of the interview:
* Sagent's unique business model, which includes maintaining high- quality, low-cost partnerships. * The company's filing of over 30 submissions to the FDA, this year. * Management's plans to launch Sagent's first product in approximately one month.
Managing Director Sharif Oussa of Blue Energy Limited (ASX:BUL), another emerging company using a sizeable portfolio to position itself for big growth, quotes, "Compared to other coal bed methane players, we have one of the largest acreage positions in the world; and we own it 100%." He adds, "We have cash in the bank and we have, potentially, one of the most significant CBM gas-in-place numbers in Australia. The company is just about to move from its exploration phase to its appraisal and development phase."
Highlights of the interview:
* A recently completed equity placement of $35 Million. * The company's 32,000 square kilometers, of which it owns 100%. * Plans to commence drilling in the next few months.
These interviews can be heard, or downloaded, at www.WallStreetReporter.com. Listeners can also subscribe to the free podcast via Apple iTunes.
Wall Street Reporter (Est. 1843) is the premier source of investment information on global small-cap public companies in high-growth sectors. Through their magazines, special reports, web site, and conferences, WSR presents unique opportunities for discovering stocks before they appear on the radar of Wall Street and have become "must-attends" and "must-reads" for the "who's who" of the investment community.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals is a specialty pharmaceuticals company focused on the improvement of existing products. The company filed over 30 submissions to the FDA this year and plans to file 70 next year. Strategy includes using over 20 partners to competitively source, develop, and manufacture their estimated $85 Billion in potential products.
About Blue Energy Limited
Blue Energy Limited is an Australian energy company focused on coal bed methane. The company's portfolio includes 100% ownership of over 32,000 acres. Having recently completed a $35 Million equity placement, the company plans to move into the appraisal and development phase and begin drilling in the next few months.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.